|
|
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors |
| 5R01CA172145-08 |
|
NCI |
2022 |
|
|
Predicting Long-Term Chemotherapy-Related Cognitive Impairment |
| 5R01CA226080-04 |
|
NCI |
2022 |
|
|
Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late Effects |
| 5R01CA248103-02 |
|
NCI |
2022 |
|
|
Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. |
| 5R01CA249988-02 |
|
NCI |
2022 |
|
|
Image-guided combination therapies for radiotherapy-induced neurocognitive impairment in pediatric brain tumor survivors |
| 5R01CA262887-02 |
|
NCI |
2022 |
|
|
Candidate mechanisms for chemotherapy-induced neurocognitive deficits in pediatric solid non-CNS tumor patients |
| 5R21CA262491-02 |
|
NCI |
2022 |
|
|
Brain iron accumulation as an in vivo quantifiable biomarker of neurocognitive dysfunction in pediatric brain tumor survivors |
| 5R21CA262978-02 |
|
NCI |
2022 |
|
|
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients |
| 5R37CA248565-03 |
|
NCI |
2022 |
|
|
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2) |
| 7R01CA172145-09 |
|
NCI |
2022 |
|
|
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL |
| 7R01CA220568-05 |
|
NCI |
2022 |
